Clinical utility of insulin and insulin analogs

The role of insulin glulisine to improve glycemic control in children with diabetes mellitus

(2016) John Carter et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

(2013) L. Meneghini et al.   DIABETES CARE

The need for better insulin therapy

(2013) G. Grunberger   DIABETES OBESITY & METABOLISM

Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2011

(2013)   DIABETES RESEARCH AND CLINICAL PRACTICE

pH-Responsive Nanoparticles Shelled with Chitosan for Oral Delivery of Insulin: From Mechanism to Therapeutic Applications

(2012) Hsing-Wen Sung et al.   ACCOUNTS OF CHEMICAL RESEARCH

The Clinical Potential of C-Peptide Replacement in Type 1 Diabetes

(2012) J. Wahren et al.   DIABETES

Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes

(2012) P. Lucidi et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries

(2012) K. Khunti et al.   DIABETES OBESITY & METABOLISM

By the numbers: New estimates from the IDF Diabetes Atlas Update for 2012

(2012) Leonor Guariguata   DIABETES RESEARCH AND CLINICAL PRACTICE

Can a Tool That Automates Insulin Titration Be a Key to Diabetes Management?

(2012) Richard M. Bergenstal et al.   Diabetes Technology & Therapeutics

Can a New Ultra-Long-Acting Insulin Analogue Improve Patient Care? Investigating the Potential Role of Insulin Degludec

(2012) Jennifer D. Robinson et al.   DRUGS

Insulin and its analogues and their affinities for the IGF1 receptor

(2012) Aimee J Varewijck et al.   ENDOCRINE-RELATED CANCER

Insulin gene therapy from design to beta cell generation

(2012) Ahter D. Sanlioglu et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Therapeutic potential of VIP vs PACAP in diabetes

(2012) Ahter D Sanlioglu et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Insulin degludec: a new ultra-longacting insulin

(2012) Abd A Tahrani et al.   LANCET

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Alan J Garber et al.   LANCET

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Simon Heller et al.   LANCET

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Early insulin treatment in type 2 diabetes: ORIGINal sin or valuable choice as ORIGINal treatment? An open debate on the ORIGIN study results

(2012) G.B. Bolli et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Effect of Insulin Analogues on Insulin/IGF1 Hybrid Receptors: Increased Activation by Glargine but Not by Its Metabolites M1 and M2

(2012) Cécile Pierre-Eugene et al.   PLoS One

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

(2012) Fei Wang et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Correlation of worldwide incidence of type 1 diabetes (DiaMond) with prevalence of asthma and atopic eczema (ISAAC)

(2011) Peter Fsadni et al.   Clinical Respiratory Journal

Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: A systematic review

(2011) P. Rys et al.   DIABETES & METABOLISM

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naive People With Type 2 Diabetes: A randomized, controlled trial

(2011) T. Heise et al.   DIABETES CARE

Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine

(2011) K. I. Birkeland et al.   DIABETES CARE

Diabetes Care for Emerging Adults: Recommendations for Transition From Pediatric to Adult Diabetes Care Systems: A position statement of the American Diabetes Association, with representation by the American College of Osteopathic Family Physicians, the American Academy of Pediatrics, the American Association of Clinical Endocrinologists, the American Osteopathic Association, the Centers for Disease Control and Prevention, Children with Diabetes, The Endocrine Society, the International Society for Pediatric and Adolescent Diabetes, Juvenile Diabetes Research Foundation International, the National Diabetes Education Program, and the Pediatric Endocrine Society (formerly Lawson Wilkins Pediatric Endocrine Society)

(2011) A. Peters et al.   DIABETES CARE

Insulin Preparations with Prolonged Effect

(2011) David R. Owens   Diabetes Technology & Therapeutics

Tracing of islet graft survival by way of in vivo fluorescence imaging

(2011) Sevim Kahraman et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Strict glycemic control and mortality risk among US adults with type 2 diabetes

(2011) Evelyn P. Davila et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

(2011) Bernard Zinman et al.   LANCET

Leptin for type 1 diabetes: coming onto stage to be (or not?)

(2011) Elif A Oral   PEDIATRIC DIABETES

Insulin Patch Pumps: Their Development and Future in Closed-Loop Systems

(2010) Henry Anhalt et al.   Diabetes Technology & Therapeutics

New Technologies in Pediatric Diabetes Care

(2010) Catherine Carchidi et al.   MCN-The American Journal of Maternal-Child Nursing

Addressing barriers to initiation of insulin in patients with type 2 diabetes

(2010) Mark Peyrot et al.   Primary Care Diabetes

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study

(2009) J. Rosenstock et al.   DIABETOLOGIA

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

(2009) L. G. Hemkens et al.   DIABETOLOGIA

Insulin Glulisine

(2009) Karly P. Garnock-Jones et al.   DRUGS

Proinsulin and the Genetics of Diabetes Mellitus

(2009) Michael A. Weiss   JOURNAL OF BIOLOGICAL CHEMISTRY

Insulin Therapy and Type 2 Diabetes: Management of Weight Gain

(2009) Samy I. McFarlane   Journal of Clinical Hypertension

New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes

(2009) W Crasto et al.   POSTGRADUATE MEDICAL JOURNAL

Molecular mechanisms of death ligand-mediated immune modulation: A gene therapy model to prolong islet survival in type 1 diabetes

(2008) Ahter Dilsad Sanlioglu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

High Levels of Endogenous Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Expression Correlate With Increased Cell Death in Human Pancreas

(2008) Ahter Dilsad Sanlioglu et al.   PANCREAS

An overview of pancreatic beta-cell defects in human type 2 diabetes: Implications for treatment

(2007) Piero Marchetti et al.   REGULATORY PEPTIDES